一种口服时具有活性的新药（AH 7725）对人体实验性哮喘的抑制作用。
Inhibition of experimental asthma in man by a new drug (AH 7725) active when given by mouth.
作者信息
Assem E S, Evans J A, McAllen M
出版信息
Br Med J. 1974 Apr 13;2(5910):93-5. doi: 10.1136/bmj.2.5910.93.
A new drug, AH 7725, with properties similar to those of disodium cromoglycate (Intal) has the additional feature of being effective when taken by mouth. Six patients with allergic asthma were studied by bronchial challenge tests with antigen. In every one the drug was found to inhibit (either partially or completely) the immediate-type asthmatic response. Late responses were not influenced. The results were significant at the 0.5% level.These findings suggest that AH 7725 given by mouth may be able to inhibit naturally occurring asthmatic attacks in allergic patients. In this case its particular advantage as a prophylactic drug would lie in the treatment of very young asthmatic children and other patients who cannot take drugs by inhalation.
一种新药AH 7725，其特性与色甘酸二钠（因他敏）相似，还有口服有效这一额外特性。对6名过敏性哮喘患者进行了抗原支气管激发试验研究。发现该药在每例患者中均能抑制（部分或完全）速发型哮喘反应。迟发型反应未受影响。结果在0.5%水平上具有显著性。这些发现表明，口服AH 7725可能能够抑制过敏性患者自然发生的哮喘发作。在这种情况下，它作为预防性药物的特殊优势在于可用于治疗非常年幼的哮喘儿童以及其他无法通过吸入用药的患者。
Zotero 插件